BridgeBio Pharma (BBIO) is trading higher today after the company announced on March 30, 2026 that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for oral BBP-418 for individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). (stocktitan.net)

An NDA submission is a major de-risking step versus a “plans to file” milestone because it formally starts the FDA’s gatekeeping process (including the agency’s decision on whether to accept the application for review). For BBIO, the BBP-418 filing is one of the company’s most watched near-term pipeline catalysts following previously disclosed positive Phase 3 FORTIFY results and the company’s stated intention to submit in the first half of 2026. (investor.bridgebio.com)

Near-term focus is likely to shift to (1) FDA acceptance for review and any timing the company provides around the review path, (2) any additional clinical or safety details that clarify how BBP-418 could be positioned if approved, and (3) BridgeBio’s broader 2026 milestone cadence across its late-stage programs, which the company has highlighted in recent updates. (investor.bridgebio.com)